Log in

NASDAQ:ACRS - Aclaris Therapeutics Stock Price, Forecast & News

$1.23
-0.14 (-10.22 %)
(As of 02/27/2020 03:27 AM ET)
Today's Range
$1.21
Now: $1.23
$1.44
50-Day Range
$1.24
MA: $1.55
$2.18
52-Week Range
$0.74
Now: $1.23
$7.51
Volume767,143 shs
Average Volume911,182 shs
Market Capitalization$50.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.06
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRS
CUSIPN/A
Phone484-324-7933

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.09 million
Book Value$5.26 per share

Profitability

Net Income$-132,740,000.00
Net Margins-1,165.39%

Miscellaneous

Employees169
Market Cap$50.91 million
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive ACRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.


Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics Inc (NASDAQ:ACRS) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($1.34) EPS for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.80. The biotechnology company earned $0.98 million during the quarter, compared to the consensus estimate of $5.87 million. Aclaris Therapeutics had a negative net margin of 1,165.39% and a negative return on equity of 83.22%. View Aclaris Therapeutics' Earnings History.

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Aclaris Therapeutics.

What price target have analysts set for ACRS?

5 Wall Street analysts have issued 12 month price objectives for Aclaris Therapeutics' stock. Their forecasts range from $5.00 to $13.00. On average, they anticipate Aclaris Therapeutics' share price to reach $9.00 in the next year. This suggests a possible upside of 631.7% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.

What is the consensus analysts' recommendation for Aclaris Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics.

Has Aclaris Therapeutics been receiving favorable news coverage?

News articles about ACRS stock have been trending extremely negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aclaris Therapeutics earned a news sentiment score of -4.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Aclaris Therapeutics.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 3,410,000 shares, an increase of 11.4% from the January 30th total of 3,060,000 shares. Based on an average daily volume of 654,200 shares, the days-to-cover ratio is currently 5.2 days. Approximately 10.2% of the company's stock are sold short. View Aclaris Therapeutics' Current Options Chain.

Who are some of Aclaris Therapeutics' key competitors?

What other stocks do shareholders of Aclaris Therapeutics own?

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the folowing people:
  • Dr. Neal S. Walker D.O., Co-Founder, CEO, Pres & Director (Age 49)
  • Mr. Christopher V. Powala, Co-Founder and Chief Regulatory & Devel. Officer (Age 60)
  • Dr. Stuart D. Shanler, Co-Founder & Chief Scientific Officer (Age 58)
  • Mr. Frank Ruffo, Co-Founder & CFO (Age 53)
  • Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 60)

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include MFN Partners Management LP (9.66%), Renaissance Technologies LLC (6.72%), EcoR1 Capital LLC (5.04%), Broadfin Capital LLC (4.56%), Man Group plc (3.13%) and Geode Capital Management LLC (1.40%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, James E Flynn, Kamil Ali-Jackson, Neal Walker and Stephen A Tullman. View Institutional Ownership Trends for Aclaris Therapeutics.

Which major investors are selling Aclaris Therapeutics stock?

ACRS stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Alambic Investment Management L.P. and Virtu Financial LLC. View Insider Buying and Selling for Aclaris Therapeutics.

Which major investors are buying Aclaris Therapeutics stock?

ACRS stock was bought by a variety of institutional investors in the last quarter, including MFN Partners Management LP, EcoR1 Capital LLC, Renaissance Technologies LLC, Broadfin Capital LLC, Parkman Healthcare Partners LLC, Jacobs Levy Equity Management Inc., Bank of New York Mellon Corp and Geode Capital Management LLC. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $1.23.

How big of a company is Aclaris Therapeutics?

Aclaris Therapeutics has a market capitalization of $50.91 million and generates $10.09 million in revenue each year. The biotechnology company earns $-132,740,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.View Additional Information About Aclaris Therapeutics.

What is Aclaris Therapeutics' official website?

The official website for Aclaris Therapeutics is http://www.aclaristx.com/.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]


MarketBeat Community Rating for Aclaris Therapeutics (NASDAQ ACRS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  320 (Vote Outperform)
Underperform Votes:  286 (Vote Underperform)
Total Votes:  606
MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe ACRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel